Baidu
map

《药神》里的进口抗癌药会降价吗?国产仿制药通过一致性评价

2018-07-06 包雨朦 澎湃新闻

电影《我不是药神》近日大火,其中表现的进口抗癌药贵、病人用药难的主题,再度引发社会各界关注。在电影中用于治疗慢粒白血病的“诺瓦”公司生产的“格列宁”,售价高达4万元一瓶,而印度生产的仿制药价格仅为500元,却能和原版达到类似的效果。据记者了解, “格列宁”的原型——瑞士诺华公司生产的格列卫(通用名:甲磺酸伊马替尼)在2013年4月专利保护失效之后,2013年6月到2014年10月间三款国产仿制药拿

电影《我不是药神》近日大火,其中表现的进口抗癌药贵、病人用药难的主题,再度引发社会各界关注。在电影中用于治疗慢粒白血病的“诺瓦”公司生产的“格列宁”,售价高达4万元一瓶,而印度生产的仿制药价格仅为500元,却能和原版达到类似的效果。

据记者了解, “格列宁”的原型——瑞士诺华公司生产的格列卫(通用名:甲磺酸伊马替尼)在2013年4月专利保护失效之后,2013年6月到2014年10月间三款国产仿制药拿到了生产批文。但这些仿制药的药效仍面临质疑,这也让格列卫继续维持高价销售。

近日,澎湃新闻记者获悉,江苏豪森药业生产的伊马替尼(商品名:昕维)已经通过了国家仿制药一致性评价,是国内首个通过评价的国产产品,这意味着,昕维达到了与格列卫一致的效果。

而这有可能进一步拉低国内市场该类药品的进口药价格。

据丁香园旗下的Insight 药品数据库信息显示,江苏豪森药业于7月5日收到了国家药品监督管理局核准签发的化学药品伊马替尼的《药品补充申请批件》,国家药审中心审评建议为通过一致性评价。

格列卫2002年在中国上市,当时的定价为23500元(100mg*120)。进入中国市场的第二年,格列卫就加入了中华慈善总会的患者援助项目,即买三盒赠六盒,起初该福利政策仅对低保患者适用,后来又扩大到全部患者群体。按照一般的用量,格列卫一日服用4粒,即便加入了援助计划,患者使用格列卫的年花费依然将近10万。

2015年陆勇代购药品案爆发,格列卫承诺降价,定价从23500元降至21000元左右。按照买三盒赠六盒的福利,该药品的实际价格已经降至7000元/盒。

当然,这比国产仿制药的价格仍要高出不少。

根据某药品电商网站的价格信息,江苏豪森的昕维(100mg*60)售价为1885元,相同规格的石药欧意生产的诺利宁定价为675元;而正大天晴生产的格尼可(100mg*12)则为380元。诺利宁的定价最低,昕维、格尼可的价格约为格列卫的一半。

进口与国产甲磺酸伊马替尼在江苏、四川、北京的中标价对比

尽管如此,格列卫在专利到期以后,并没有丧失市场优势,依然是慢粒白血病治疗领域需求量最大的药物。

Insight数据库显示,原研厂家诺华的格列卫 (销售额为 15.4 亿元)市场份额最高,为80.29%,江苏豪森的昕维(销售额为2.1亿元)市场份额为10.97%,正大天晴的格尼可 (销售额为1.6亿元) 市场份额为8.53%,石药欧意的诺利宁市场份额为0.21%。

一般而言,进口原研药在专利期过了之后,由于大量廉价国产仿制药的出现,往往会面临断崖式的销量下跌。这一情况之所以没有在格列卫上发生,主要原因可能是此前国产仿制药的药效不敌原版产品,并且可能出现副作用。

仿制药一致性评价是我国目前针对国产仿制药质量良莠不齐而展开的一项旨在肃清市场的重点工作。2016年3月5日,国务院办公厅发布《关于开展仿制药质量和疗效一致性评价的意见》(下称《意见》),要求对国家基本药物目录(2012年版)中2007年10月1日前批准上市的化学药品仿制药在2018年底前完成一致性评价,以证明与原研药药效一致。

有分析认为,随着国产仿制药得到一致性评价的认可,将进一步分割格列卫的市场份额,患者可以以更低的用药成本获得相同的治疗效果。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1906875, encodeId=43e719068e540, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Mon Apr 29 19:27:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261420, encodeId=71071261420a8, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314770, encodeId=64431314e70bc, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425025, encodeId=5cb314250256c, content=<a href='/topic/show?id=c1219810ebf' target=_blank style='color:#2F92EE;'>#降价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98107, encryptionId=c1219810ebf, topicName=降价)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6933946754, createdName=30397605, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444395, encodeId=dfe01444395ca, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528025, encodeId=397d1528025e1, content=<a href='/topic/show?id=36848e9450d' target=_blank style='color:#2F92EE;'>#药神#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87945, encryptionId=36848e9450d, topicName=药神)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5611876990, createdName=qingting, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329851, encodeId=65003298511b, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Jul 07 00:13:24 CST 2018, time=2018-07-07, status=1, ipAttribution=)]
    2019-04-29 zhanfl
  2. [GetPortalCommentsPageByObjectIdResponse(id=1906875, encodeId=43e719068e540, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Mon Apr 29 19:27:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261420, encodeId=71071261420a8, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314770, encodeId=64431314e70bc, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425025, encodeId=5cb314250256c, content=<a href='/topic/show?id=c1219810ebf' target=_blank style='color:#2F92EE;'>#降价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98107, encryptionId=c1219810ebf, topicName=降价)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6933946754, createdName=30397605, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444395, encodeId=dfe01444395ca, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528025, encodeId=397d1528025e1, content=<a href='/topic/show?id=36848e9450d' target=_blank style='color:#2F92EE;'>#药神#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87945, encryptionId=36848e9450d, topicName=药神)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5611876990, createdName=qingting, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329851, encodeId=65003298511b, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Jul 07 00:13:24 CST 2018, time=2018-07-07, status=1, ipAttribution=)]
    2018-07-08 drwjr
  3. [GetPortalCommentsPageByObjectIdResponse(id=1906875, encodeId=43e719068e540, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Mon Apr 29 19:27:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261420, encodeId=71071261420a8, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314770, encodeId=64431314e70bc, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425025, encodeId=5cb314250256c, content=<a href='/topic/show?id=c1219810ebf' target=_blank style='color:#2F92EE;'>#降价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98107, encryptionId=c1219810ebf, topicName=降价)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6933946754, createdName=30397605, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444395, encodeId=dfe01444395ca, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528025, encodeId=397d1528025e1, content=<a href='/topic/show?id=36848e9450d' target=_blank style='color:#2F92EE;'>#药神#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87945, encryptionId=36848e9450d, topicName=药神)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5611876990, createdName=qingting, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329851, encodeId=65003298511b, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Jul 07 00:13:24 CST 2018, time=2018-07-07, status=1, ipAttribution=)]
    2018-07-08 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=1906875, encodeId=43e719068e540, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Mon Apr 29 19:27:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261420, encodeId=71071261420a8, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314770, encodeId=64431314e70bc, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425025, encodeId=5cb314250256c, content=<a href='/topic/show?id=c1219810ebf' target=_blank style='color:#2F92EE;'>#降价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98107, encryptionId=c1219810ebf, topicName=降价)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6933946754, createdName=30397605, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444395, encodeId=dfe01444395ca, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528025, encodeId=397d1528025e1, content=<a href='/topic/show?id=36848e9450d' target=_blank style='color:#2F92EE;'>#药神#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87945, encryptionId=36848e9450d, topicName=药神)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5611876990, createdName=qingting, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329851, encodeId=65003298511b, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Jul 07 00:13:24 CST 2018, time=2018-07-07, status=1, ipAttribution=)]
    2018-07-08 30397605
  5. [GetPortalCommentsPageByObjectIdResponse(id=1906875, encodeId=43e719068e540, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Mon Apr 29 19:27:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261420, encodeId=71071261420a8, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314770, encodeId=64431314e70bc, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425025, encodeId=5cb314250256c, content=<a href='/topic/show?id=c1219810ebf' target=_blank style='color:#2F92EE;'>#降价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98107, encryptionId=c1219810ebf, topicName=降价)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6933946754, createdName=30397605, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444395, encodeId=dfe01444395ca, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528025, encodeId=397d1528025e1, content=<a href='/topic/show?id=36848e9450d' target=_blank style='color:#2F92EE;'>#药神#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87945, encryptionId=36848e9450d, topicName=药神)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5611876990, createdName=qingting, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329851, encodeId=65003298511b, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Jul 07 00:13:24 CST 2018, time=2018-07-07, status=1, ipAttribution=)]
    2018-07-08 huagfeg
  6. [GetPortalCommentsPageByObjectIdResponse(id=1906875, encodeId=43e719068e540, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Mon Apr 29 19:27:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261420, encodeId=71071261420a8, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314770, encodeId=64431314e70bc, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425025, encodeId=5cb314250256c, content=<a href='/topic/show?id=c1219810ebf' target=_blank style='color:#2F92EE;'>#降价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98107, encryptionId=c1219810ebf, topicName=降价)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6933946754, createdName=30397605, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444395, encodeId=dfe01444395ca, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528025, encodeId=397d1528025e1, content=<a href='/topic/show?id=36848e9450d' target=_blank style='color:#2F92EE;'>#药神#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87945, encryptionId=36848e9450d, topicName=药神)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5611876990, createdName=qingting, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329851, encodeId=65003298511b, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Jul 07 00:13:24 CST 2018, time=2018-07-07, status=1, ipAttribution=)]
    2018-07-08 qingting
  7. [GetPortalCommentsPageByObjectIdResponse(id=1906875, encodeId=43e719068e540, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Mon Apr 29 19:27:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261420, encodeId=71071261420a8, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314770, encodeId=64431314e70bc, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425025, encodeId=5cb314250256c, content=<a href='/topic/show?id=c1219810ebf' target=_blank style='color:#2F92EE;'>#降价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98107, encryptionId=c1219810ebf, topicName=降价)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6933946754, createdName=30397605, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444395, encodeId=dfe01444395ca, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528025, encodeId=397d1528025e1, content=<a href='/topic/show?id=36848e9450d' target=_blank style='color:#2F92EE;'>#药神#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87945, encryptionId=36848e9450d, topicName=药神)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5611876990, createdName=qingting, createdTime=Sun Jul 08 13:27:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329851, encodeId=65003298511b, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sat Jul 07 00:13:24 CST 2018, time=2018-07-07, status=1, ipAttribution=)]
    2018-07-07 phoebeyan520

    谢谢分享.学习了

    0

Baidu
map
Baidu
map
Baidu
map